What is Arena Pharmaceuticals Price-to-Free-Cash-Flow?
As of today (2024-04-26), Arena Pharmaceuticals's share price is $99.99.
Arena Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $-8.60. Hence, Arena Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Arena Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Arena Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 183.33. The lowest was 0.00. And the median was 5.28.
ARNA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -45.00% per year.
During the past 13 years, Arena Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 50.40% per year. The lowest was -47.30% per year. And the median was 1.50% per year.
Arena Pharmaceuticals Price-to-Free-Cash-Flow Historical Data
The historical data trend for Arena Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arena Pharmaceuticals's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Arena Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arena Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Arena Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Arena Pharmaceuticals's Share Price of today is $99.99. Arena Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.60.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Arena Pharmaceuticals Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Arena Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARNA has been successfully added to your 